Cancéropôle Nord-Ouest

What Cancéropôle Nord-Ouest does

Cancéropôle Nord-Ouest (CNO) is a French public-interest group (Groupement d'Intérêt Public, GIP) that coordinates cancer research across the Hauts-de-France and Normandy inter-region. Established in 2003 and headquartered in Lille, the consortium binds together four university hospitals (CHUs Amiens, Caen, Lille, Rouen), three Centres de Lutte contre le Cancer (François Baclesse, Oscar Lambret, Henri Becquerel), Inserm, CNRS and four universities under a 14-member Board of Directors. It structures activity around five thematic axes — precision medicine for solid tumors, clinical and biological aspects of malignant hemopathies, molecular imaging and therapeutic adaptation, cancer-brain-cognition, and cancer-individual-society — supported by seven working groups and three research platforms (Cancer et Cognition, MapInMed, OrgaNO).

CNO's operational portfolio comprises the ARCHIMAID clinical trial directory covering more than 50 health establishments, the StARCC clinical research structuring program involving 19 establishments, the unique-in-France DIU Cancer et Cognition diploma, and recurring scientific events such as the annual Journées Scientifiques, Translationnelles workshops and Immuno-Oncologie days. Funding flows are institutional rather than commercial: the entity holds INCa labeling for 2023-2027 and is financed by grants from the Institut National du Cancer, the Hauts-de-France and Normandy regional councils, and co-funding from GEFLUC, Fondation ARC, BMS Foundation, SATT Nord (technology transfer), Thellie (crowdfunding), MATWIN/OncoSTART (entrepreneurship), Unicancer and GIRCI Nord-Ouest, supplemented by EU-level participation in TRANSCAN-3.

The consortium has a core operating team of 5 employees, does not commercialize products, and has no conventional revenue. Its role is to provide project funding through multiple calls for projects (Emergence, Structuration, Mobilité, Évènements, GEFLUC/CNO, GIRCI/CNO), to coordinate translational and clinical research, and to serve as the single-entry point for cancer research valorization in the inter-region. President Dominique Chevalier was elected on June 20, 2025, succeeding Guy Launoy.

Name

Cancéropôle Nord-Ouest

Legal name

Cancéropôle Nord-Ouest

Website

https://canceropole-nordouest.org

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Cancéropôle Nord-Ouest is a French public-interest group (GIP) that coordinates and funds cancer research across the Hauts-de-France and Normandy regions, linking 14 institutional members — university hospitals, cancer centers, Inserm, CNRS and universities — under INCa labeling for 2023-2027.

Ownership category

akta.pro rank

Product category

Cancer Research Coordination Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

akta.pro secondary industries

Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC), Provider Directory & Network Identity (HPD, NPI, credential linking) (HLACABAF)

Keywords

• Cancer research coordination
• Oncology research consortium
• Translational cancer research
• Clinical research funding
• Public health research

Headquarters

HQ city

Nord-Ouest Region (Hauts-de-France & Normandy)

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others, Technology or R&D, Marketing or Sales

Revenue model

1. Public Institutional Funding: The Cancéropôle Nord-Ouest is a public interest group (GIP) funded primarily through institutional grants from the Institut National du Cancer (INCa), regional councils (Hauts-de-France, Normandy), and potentially the French Ministry of Health. Funding supports AAPs, scientific events, platforms, and consortium operations.
2. Partnership-Based Funding: The consortium receives co-funding from private partners such as GEFLUC, Fondation ARC, and BMS Foundation for specific calls for projects and events. It also co-invests with SATT Nord in technology transfer.
3. Crowdfunding via Thellie: A partnership with Thellie, a crowdfunding platform, enables direct public donations to fund specific research projects selected by the Cancéropôle.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Cancéropôle Nord-Ouest (CNO) is a public interest group (GIP) that coordinates, funds, and structures cancer research across the Hauts-de-France and Normandy inter-region of France. It operates dedicated research platforms (Cancer et Cognition, MapInMed, OrgaNO), manages calls for projects (AAP Emergence, Structuration, Mobilité, Events), and runs the inter-regional ARCHIMAID clinical trial directory covering 50+ healthcare establishments.

Product overview

Cancéropôle Nord-Ouest is a public interest group (GIP) that serves as a cancer research cluster for the Hauts-de-France and Normandy regions in France. The organization operates as a coordination and funding body rather than a product company. Its portfolio consists of research platforms (Cancer et Cognition, MapInMed, OrgaNO), the ARCHIMAID clinical trial directory, funding programs (AAP Emergence and Structuration), training programs (DIU Cancer et Cognition), event organization (Journées Scientifiques), and clinical research initiatives (StARCC, CLIP²). The structure is decentralized across five research axes covering precision medicine for solid tumors, hematologic malignancies, molecular imaging, cancer neuroscience, and cancer and society.

Differentiator

Problem solved

Functional benefit

Brands

• Plateforme Cancer et Cognition: Platform focused on cancer-related cognitive issues and quality of life research
• Plateforme MapInMed
• Réseau OrgaNO

Products and services

• ARCHIMAID Clinical Trial Directory Inter-regional directory of open clinical trials in oncology covering more than 50 health establishments in the Hauts-de-France and Normandy regions, accessible via archimaid.fr. Enables health professionals and patients to search for trials by keywords, location, specialty, or ClinicalTrials.gov references, with newsletter subscriptions for trial openings.
• Plateforme Cancer et Cognition Research platform focused on cancer-related cognitive issues, studying cognitive disorders in cancer patients. Supports research on quality of life, delivers the DIU Cancer et Cognition inter-university training program (unique in France), and hosts interdisciplinary working groups.
• Plateforme MapInMed National platform dedicated to studying and reducing social inequalities in cancer. Focused on epidemiology, prevention, and cancer screening, with particular attention to socio-economic and geographic disparities in cancer outcomes across the inter-region.
• Réseau OrgaNO Inter-regional network coordinating two organoid research platforms (ORGAPRED in Caen and ORGARES in Lille) for producing tumor organoids used as preclinical models in cancer research.
• StARCC (Structuration de l'Activité de Recherche Clinique en Cancérologie) Inter-regional initiative bringing together Hauts-de-France and Normandy to increase patient enrollment in clinical trials, promote therapeutic innovation access, improve clinical research visibility, and optimize collaborations with sponsors. Involves 19 public and private health establishments and is co-managed with CLIP² Lille.
• OncoSTART Summit Annual entrepreneurship summit dedicated to oncology, featuring startup pitches, job dating, and best practice sharing for oncology entrepreneurs. Organized under the OncoSTART consortium in which CNO is a founding member.
• DIU Cancer et Cognition Training Program Inter-university diploma (Diplôme Inter-Universitaire) on cognitive disorders in cancer patients, unique in France. Covers cognitive impairment related to cancer and its treatments. Offered in partnership with universities and the Plateforme Cancer et Cognition.
• Appels à Projets (AAP) - Research Funding Programs Recurring competitive funding programs (Calls for Projects) supporting cancer research across the inter-region. Categories include Emergence (seed funding for new projects), Structuration (100,000 euros per project for 18-24 months for national/European positioning), Mobilité (mobility grants), Évènements (event funding), and co-funded AAPs with GIRCI and GEFLUC (10,000 euros for young researchers).
• Journées Scientifiques du CNO Annual scientific conference organized by Cancéropôle Nord-Ouest (17th edition in 2025, 18th edition planned for 2026), bringing together hundreds of researchers from the Hauts-de-France and Normandy regions with sessions covering all five research axes. Includes call for communications and poster sessions.

Quantifiable outcome

• 9 projects funded through the Emergence AAP 2024; 2 projects (CANCER STOP and COMBREAST) funded through the Structuration AAP 2024; 100,000 euros per structuring project for 18-24 months.
• +3 more outcomes

Named customers13 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core, supporting and major.

• OncoSTART ConsortiumcoreStrategic or Co-development Partner · 1 June 2021Cancéropôle Nord-Ouest is one of 12 expert actors in the OncoSTART consortium, created at the initiative of MATWIN (French oncology innovation accelerator). The consortium gathers and synergizes national-level expertise, know-how, and networks to boost entrepreneurship in oncology. CNO participates in OncoSTART Entrepreneurship Schools and the annual OncoSTART Summit.
• SATT Nord (Société d'Accélération du Transfert de Technologies Nord)coreStrategic or Co-development Partner · 21 June 2019SATT Nord and Cancéropôle Nord-Ouest signed a formal partnership agreement on 21 June 2019 to jointly work on maximizing technology transfer and economic valorization of cancer research results. The partnership provides researchers with a single-entry point via the CNO for valorization support and combines the expertise of both organizations to accelerate deployment of innovative cancer treatments.
• Thellie (Plateforme de financement participatif)supportingGTM or Marketing Partner · 1 December 2018Cancéropôle Nord-Ouest signed a partnership convention with Thellie, a crowdfunding platform dedicated to medical research funding. Thellie enables donors to specifically target cancer research projects they wish to support, with 100% of donations redirected to researchers' projects. The CNO supports several projects annually through this platform.
• ARCHIMAID (Inter-regional Clinical Trial Directory)coreTechnology or IntegrationARCHIMAID is an inter-regional directory of open clinical trials in oncology covering more than 50 health establishments in the Nord-Ouest. Developed under the StARCC project and hosted at archimaid.fr, it enables health professionals to search for trials by keywords, location, and specialty, with newsletter subscriptions for trial openings.
• StARCC (Structuration de l'Activité de Recherche Clinique en Cancérologie)coreStrategic or Co-development PartnerStARCC is an inter-regional initiative bringing together Hauts-de-France and Normandy for clinical research structuring. In the Nord and Pas-de-Calais alone, StARCC involves 19 public and private health establishments. The project is co-managed with CLIP² Lille (Centre Labellisé INCa pour les Phases Précoces) and issues quarterly newsletters.
• CLIP² Lille (Centre Labellisé INCa pour les Phases Précoces)coreStrategic or Co-development PartnerCLIP² Lille, jointly constituted by CHU de Lille and Centre Oscar Lambret, is one of 16 CLIP² centers in France, and one of 7 doubly labeled for child/adult. It collaborates with StARCC on clinical trial coordination and newsletter dissemination across the inter-region.
• TRANSCAN-3 (European Cancer Research Consortium)majorStrategic or Co-development PartnerTRANSCAN-3 is a European consortium launching joint transnational calls for proposals in cancer research. CNO acts as the national contact point for French teams. The JTC 2024 call focuses on 'Combination therapies against cancer: new opportunities for translational research', with pre-proposal deadline of 5 July 2024.
• Plateforme Nationale Qualité de Vie et CancersupportingStrategic or Co-development PartnerCancéropôle Nord-Ouest hosts the Nord-Ouest antenna of the national Quality of Life and Cancer platform. The platform is labeled by the Ligue Nationale contre le Cancer and supported by INCa through the Cancéropôles. It fosters collaborative projects and provides multidisciplinary expertise for quality-of-life measurement in oncology studies.
• UnicancercoreStrategic or Co-development PartnerUnicancer, the federation of French cancer centers, collaborates with CNO on innovation prizes, patient representation in governance (e.g., Emmanuelle Hoche), and the DIU Cancer et Cognition training program. Centre Oscar Lambret and Centre Henri Becquerel (Unicancer members) are represented on CNO's Board.
• GIRCI Nord-Ouest (Groupement Interrégional de Recherche Clinique et d'Innovation)coreStrategic or Co-development PartnerGIRCI Nord-Ouest and CNO issue joint calls for projects (e.g., 'Aide à l'Emergence') supporting young clinical research teams. The StARCC project is a joint initiative, and GIRCI-NO publishes regular newsletters on inter-regional clinical research activity.
• MATWIN (Oncology Innovation Accelerator)coreStrategic or Co-development PartnerMATWIN is the French accelerator for oncology innovation that initiated the OncoSTART consortium. CNO participates as a founding member, supporting entrepreneurship events, startup showcase programs, and startup pitching competitions at events like MEET2WIN.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Others

• SATT Nord: French technology transfer acceleration company and formal partner of CNO since 2019. Adjacent rather than competing — SATT Nord provides the commercialization pathway that complements CNO's research coordination role for cancer innovations in the Nord-Ouest.
• MATWIN: French oncology innovation accelerator that initiated the OncoSTART consortium of which CNO is a founding member. Adjacent enabling player — supports the entrepreneurship track that complements CNO's academic research coordination.

Broad incumbents

• EORTC: European Organisation for Research and Treatment of Cancer, a larger international cancer clinical research cooperative. Comparable in its coordination of multi-site oncology clinical trials and translational research, but operating at the European rather than regional scale.
• Institut National du Cancer (INCa): French national cancer agency that labels and funds the Canceropôle network. While not a direct peer, INCa is the upstream regulator and primary funder that defines CNO's mandate, evaluation criteria, and funding cycles — making it the most important institutional counterpart.

Direct peers

• Cancéropôle PACA: Provence-Alpes-Côte d'Azur Canceropôle and one of 16 INCa-labeled regional structures. Direct peer with identical institutional form (GIP), mandate, and operational model focused on coordinating cancer research and clinical trial activity across member institutions.
• Cancéropôle CLARA: One of the other 16 French regional Canceropôles labeled by INCa, covering the Lyon Auvergne-Rhône-Alpes region. Directly comparable as a GIP-funded cancer research coordinator operating under the same INCa mandate, with similar AAP funding programs and research axes.
• Cancéropôle Grand Ouest: Western France (Rennes/Nantes) Canceropôle, INCa-labeled. Direct peer operating under identical INCa framework, with the same five-axis research structure and AAP funding programs for cancer research teams in its inter-region.
• Cancéropôle Grand Sud-Ouest: South-West France (Toulouse/Bordeaux) Canceropôle, INCa-labeled. Direct peer in the same national network, performing the same inter-regional cancer research coordination role for its member academic hospitals and universities.
• Cancéropôle Île-de-France: Paris-region Canceropôle, also INCa-labeled. Directly comparable as a peer Canceropôle coordinating cancer research across the largest French academic and hospital ecosystem, with similar working groups, AAPs, and platform model.
• Cancéropôle Est: Eastern France Canceropôle, INCa-labeled, covering Strasbourg/Nancy/Besançon/Dijon. Direct peer with the same coordination mandate, AAP portfolio, and institutional structure across its inter-region.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/canc%C3%A9rop%C3%B4le-nord-ouest

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancéropôle Nord-Ouest